Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:
“Is there a synergistic effect between enfortumab vedotin (EV) and pembrolizumab (P) for untreated advanced urothelial carcinoma in clinical setting?
This analysis suggests no! EV+P seems to follow a an independent drug action model with no evidence of synergy.”
Title: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma
Authors: Ryan D. Chow, Ronac Mamtani
More posts featuring Raffaele Colombo.